CNBX PHARMACEUTICALS INC.: 10-Q filed 2022-01-13
What CNBX PHARMACEUTICALS INC. reported in its quarterly report filed 2022-01-13 (fiscal Q1 2022): 21 published measures, 46 facts as tagged in accession 0001683168-22-000244.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-01-13
- Fiscal period
- fiscal Q1 2022
- Accession
- 0001683168-22-000244 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 2,120,179 | USD | |
| At 2021-08-31 | 3,078,961 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 627,421 | USD | |
| At 2021-08-31 | 1,805,914 | USD | |
| At 2020-11-30 | 1,255,844 | USD | |
| At 2020-08-31 | 1,764,524 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 786,414 | USD | |
| At 2021-08-31 | 1,386,472 | USD | |
| At 2020-11-30 | 184,031 | USD | |
| At 2020-08-31 | 777,611 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | -1,323,020 | USD | 91 |
| 2020-09-01 to 2020-11-30 | -654,767 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | -599,545 | USD | 91 |
| 2020-09-01 to 2020-11-30 | -592,637 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | -513 | USD | 91 |
| 2020-09-01 to 2020-11-30 | -943 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | -18,148,738 | USD | |
| At 2021-08-31 | -16,825,718 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 591,586 | USD | |
| At 2021-08-31 | 642,896 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | 425,737 | USD | 91 |
| 2020-09-01 to 2020-11-30 | 0 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | -1,110,349 | USD | 91 |
| 2020-09-01 to 2020-11-30 | -659,732 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 964,586 | USD | |
| At 2021-08-31 | 1,590,847 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 1,492,758 | USD | |
| At 2021-08-31 | 1,273,046 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | 1,110,349 | USD | 91 |
| 2020-09-01 to 2020-11-30 | 659,732 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | 440,044 | USD | 91 |
| 2020-09-01 to 2020-11-30 | 433,730 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 148,661,247 | shares | |
| At 2021-08-31 | 148,661,247 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | 17,489,100 | USD | |
| At 2021-08-31 | 17,063,363 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-11-30 | -2,186,926 | USD | |
| At 2021-08-31 | -1,905,715 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | -1,604,231 | USD | 91 |
| 2020-09-01 to 2020-11-30 | -541,680 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | 666,485 | USD | 91 |
| 2020-09-01 to 2020-11-30 | 218,451 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | 51,823 | USD | 91 |
| 2020-09-01 to 2020-11-30 | 57,505 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2021-11-30 | -212,670 | USD | 91 |
| 2020-09-01 to 2020-11-30 | 4,965 | USD | 91 |
Inspect the source
- Entity
- CNBX PHARMACEUTICALS INC. / CIK 0001343009
- Captured
- 2026-09-20T07:54:32.519Z
- SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))